focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 250 movers: Miners drag index down, Synthomer spikes higher

Tue, 11th Aug 2015 14:15

(ShareCast News) - The FTSE 250 index was by late on Tuesday afternoon giving up some of the gains made late the day before, as commodities-focused stocks were hit by China's devaluation and corporate news received mixed reviews.By 1540 BST the index was down 0.47% at 17,677.29 points, with Vedanta Resources losing most of the ground that it had gained on Monday.Other mid-cap basic resources hit as the dollar appreciated 1.8% against China's yuan included copper producer Kaz Minerals, Premier Oil and platinum miner Lonmin.Although its shares gained initially, Just Retirement was firmly in the red later in the day after agreeing a 60-40 merger in its favour with annuities rival Partnership Assurance to create a new £1.7bn company.Woodford Patient Capital Trust, one of the funds run by star fund manager Neil Woodford, was lower despite after publishing first half-year results since listing in April this year, with the shares trading at an 11% premium to net assets value per share. But the shares were hit by the announcement of a tap issuance programme to satisfy excess demand in the secondary market, but the new shares issued will be done so at a premium to NAV and should therefore be accretive to existing shareholders.Building materials group SIG fell despite posting a rise in first-half pre-tax profit and raising its interim dividend. The company said its margins were under pressure, with variable trading conditions in Europe and a significant weakening of the euro which hit revenues.Leading the 250 risers on Tuesday was Synthomer, as the latex maker reported a first-half profit before tax of £51.4m, up 14% from the first half of last year. The company said the performance was strong given significant exchange rate headwinds, and warned its full year result could suffer if conditions continued.Online and catalogue retailer N Brown was lifted despite the release of mixed UK retail sales data from the BRC. Online non-food sales rose by 14.7%, higher than expected, but ladieswear had a disappointing month, though accessories, kidswear and summer footwear enjoyed strong sales.Allied Minds, after being revealed as one of the stocks in the Woodford Patient Capital Trust's top ten holdings, was another big gainer. (4d Pharma and Vernalis, an AIM company, also gained strongly later in the session, though Imperial Innovations was a faller, disproving any Woodford-based stock picking strategies.)FTSE 250 - RisersSynthomer (SYNT) 350.80p +6.40%Allied Minds (ALM) 471.50p +5.88%Zoopla Property Group (WI) (ZPLA) 257.90p +5.65%Nostrum Oil & Gas (NOG) 570.00p +3.92%Euromoney Institutional Investor (ERM) 1,115.00p +3.82%Cineworld Group (CINE) 550.00p +3.38%Centamin (DI) (CEY) 55.05p +2.42%Evraz (EVR) 97.75p +2.20%Brown (N.) Group (BWNG) 322.00p +2.09%Acacia Mining (ACA) 241.20p +1.99%FTSE 250 - FallersVedanta Resources (VED) 468.00p -4.76%Shawbrook Group (SHAW) 324.60p -4.36%Kaz Minerals (KAZ) 156.70p -3.81% Just Retirement Group (JRG) 191.20p -3.77%Woodford Patient Capital Trust (WPCT) 115.50p -3.19%Premier Oil (PMO) 119.50p -3.00%Lonmin (LMI) 43.05p -2.93%SIG (SHI) 196.10p -2.58%Brewin Dolphin Holdings (BRW) 301.00p -2.40%Ocado Group (OCDO) 374.30p -2.32%
More News
17 May 2022 11:07

IN BRIEF: 4D Pharma rises as asthma drug moves on to part B of trial

4D Pharma PLC - Leeds, England-based pharmaceutical company - Says part A of the phase I/II trial of MRx-4DP0004 for the treatment of asthma showed that a greater amount of patients receiving the drug than those receiving placebo experienced a reduction in asthma control questionnaire scores. Reports that a greater proportion of the MRx-4DP0004 group than the placebo group experienced a reduction in the total weekly use of rescue medication at all time points. Adds that 50% of patients receiving the drug experienced "clinically meaningful" improvements in asthma quality of life questionnaire scores. Says MRx-4DP0004 is progressing to part B of the trial. Plans to enrol asthma patients with more symptomatic disease. Expects this to give a greater scope for treatment effects to be observed.

Read more
1 Apr 2022 09:56

AIM WINNERS & LOSERS: Quiz shares in style as sales top expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
1 Apr 2022 08:11

IN BRIEF: 4D Pharma annual pretax loss widens, sees itself well-funded

4D Pharma PLC - Leeds, England-based pharmaceutical company - Posts widened pretax loss for 2021. Pretax loss stretches to GBP57.5 million from GBP30.3 million the year before.

Read more
23 Mar 2022 11:21

AIM WINNERS & LOSERS: RWS and James Cropper sink on profit warnings

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
23 Mar 2022 11:16

4d Pharma shares jump on positive results from cancer treatment study

(Alliance News) - 4d Pharma PLC shares soared on Wednesday after the company said that its phase I/II study for the combination of MRx0518 and Keytruda for the treatment of renal cell carcinoma showed positive results.

Read more
9 Mar 2022 19:26

IN BRIEF: 4D Pharma registers for potential ADS offering in US

4D Pharma PLC - Leeds, England-based pharmaceutical company - Files shelf registration statement to the US Securities & Exchange Commission following which the company may offer up to USD150.0 million of shares in the form of American Depositary Shares, with each ADS reflecting eight ordinary shares.

Read more
22 Feb 2022 21:57

TRADING UPDATES: Angling Direct ups revenue; Ceiba takes Omicron hit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Feb 2022 09:55

4d Pharma gets FDA clearance for potential Parkinson's treatments

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced on Tuesday that the United States Food and Drug Administration (FDA) has cleared investigational new drug applications for 'MRx0005' and 'MRx0029', for the treatment of Parkinson's disease.

Read more
27 Jan 2022 13:20

IN BRIEF: 4D Pharma sees encouraging results for MRx-4DP0004 in trial

IN BRIEF: 4D Pharma sees encouraging results for MRx-4DP0004 in trial

Read more
4 Jan 2022 10:32

IN BRIEF: 4d Pharma names John Doyle as new chief financial officer

IN BRIEF: 4d Pharma names John Doyle as new chief financial officer

Read more
13 Dec 2021 10:55

4D Pharma announces positive results in asthma treatment trials

4D Pharma announces positive results in asthma treatment trials

Read more
30 Sep 2021 11:05

4D Pharma pretax loss grows in first half after Spac merger costs

4D Pharma pretax loss grows in first half after Spac merger costs

Read more
29 Jul 2021 22:08

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

Read more
26 Jul 2021 16:23

EXECUTIVE CHANGES: Persimmon finance boss retires; Block fights Forest

EXECUTIVE CHANGES: Persimmon finance boss retires; Block fights Forest

Read more
4 Jun 2021 10:32

4D Pharma halts enrolment for Covid treatment trial, focuses on asthma

4D Pharma halts enrolment for Covid treatment trial, focuses on asthma

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.